BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

All News

FDA Briefs

Oncology Icons

Special Reports

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Precision Medicine

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Managing Anemia in Lower-Risk Myelodysplastic Syndromes (MDS) 

Overview of Low-Risk MDS: Clinical Hallmarks and Current Treatments

Video content above is prompted by the following question(s):

What are currently available treatments for anemia in patients with LR MDS?

Videos

Jamie Koprivnikar, MD, and Solly Chedid, MD, provide insights surrounding treatment management for patients diagnosed with lower-risk MDS.

Medical experts discuss currently available treatments MDS.

Drs Koprivnikar and Chedid highlight prognostic scoring systems in MDS.

Incorporating Prognostic Scoring Systems in Treatment Decisions for Lower-Risk MDS

Medical experts examine the role of luspatercept as a first-line treatment for anemia in lower-risk MDS patients, including those with RS+/RS- and serum EPO ≤200 mU/L, and discuss its efficacy and potential benefits for this population.

The Role of Luspatercept as First-Line Treatment in Lower-Risk MDS

Medical experts explore how improved hemoglobin levels with luspatercept treatment impact overall well-being and daily functioning, with insights from the post-hoc analysis of the COMMANDS study revealing relationships between hemoglobin levels and quality of life.

Impact of Improved Hemoglobin Levels on Patient Well-being and Quality of Life

Clinicians discuss personalized approaches to initiating and adjusting luspatercept dosing, considering individual patient responses and tolerability, while also examining insights from the MAXILUS study, which explored starting treatment at the maximum approved dose.

Approaches to Initiating and Adjusting Luspatercept Dosing

Experts discuss factors influencing the choice between luspatercept and erythropoiesis-stimulating agents (ESAs) for initial anemia treatment, considerations for transitioning patients from ESAs to luspatercept, optimal timing for such transitions, and the clinical benefits of luspatercept dose titration as evidenced by real-world data presented at EHA 2024.

Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)

Jamie Koprivnikar, MD, and Solly Chedid, MD, discuss ways to continue to advance the treatment landscape for lower-risk MDS, particularly in managing anemia and improving quality of life for patients.

Advancing the Treatment Landscape for Lower-Risk MDS: Unmet Needs and Future Directions

Experts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.

Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating Agents

Overview of Low-Risk MDS: Clinical Hallmarks and Current Treatments

EP: 1.Overview of Low-Risk MDS: Clinical Hallmarks and Current Treatments

EP: 2.Incorporating Prognostic Scoring Systems in Treatment Decisions for Lower-Risk MDS

EP: 3.The Role of Luspatercept as First-Line Treatment in Lower-Risk MDS

EP: 4.Impact of Improved Hemoglobin Levels on Patient Well-being and Quality of Life

EP: 5.Approaches to Initiating and Adjusting Luspatercept Dosing

EP: 6.Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)

EP: 7.Advancing the Treatment Landscape for Lower-Risk MDS: Unmet Needs and Future Directions

EP: 8.Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating Agents